Bristol-Myers Squibb Company (NYSE: BMY) has announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin (‘null responders’*).
Newly updated US antiretroviral treatment guidelines are recommending antiretroviral treatment for all people with HIV infection, with particular emphasis on treatment for: people with CD4 cell counts below 500
National Institute for Health and Clinical Excellence (NICE) in the UK has issued a Final Appraisal Determination (FAD) recommending the use of 'Victrelis'® (boceprevir) in combination with peginterferon alfa and ribavirin ('dual therapy') as an option for the treatment of genotype 1 chronic hepatitis C
An experimental HIV vaccine that's worked better than anything else tried so far is going to be tested in South Africa, U.S. health officials said Wednesday.
Newly updated US antiretroviral treatment guidelines are recommending antiretroviral treatment for all people with HIV infection, with particular emphasis on treatment for: people with CD4 cell counts below 500; anyone at risk of transmitting HIV to partners; pregnant women; and people with hepatitis B co-infection or HIV-related kidney disease.
The new recommendations strengthen previous US recommendations on when to start treatment, which recommended initiating treatment at CD4 cell counts between 350 and 500 cells/mm3. The 2009 guidelines panel was, however, divided as to the strength of this recommendation: based on available evidence, 55% of the panel considered it a 'strong' recommendation and 45% 'moderate'. The 2009 guidelines panel also noted that it was split on whether to recommend treatment at CD4 counts above 500.
The new Department of Health and Human Services (DHHS) guidelines state that panel members were evenly divided between recommending therapy at CD4 counts above 500 and considering it optional, but this caveat is presented within an overall framework that now states “antiretroviral therapy is recommended for all HIV-infected individuals”.
In support of this recommendation, the new guidelines cite a range of evidence showing associations between viral replication and increased risk of illness and death in people with HIV, but do not discuss the absolute reduction in risk that might be associated with earlier treatment, nor the number of people who would need to receive treatment in order to prevent one new death or event in a year.
To read more on this subject visit : www.http://www.aidsmap.com/page/2295568/
© Copyright 2011 Positive Nation, Talent Media.
Designd & powerd by ENTWURF.